Siwa Therapeutics
  • Home
  • Leadership
  • Science
    • Senescence
    • Diseases
  • Data
    • SIWA 318
    • Data
    • Other Products
  • Media
    • News
    • Videos
  • Partners
  • Contact

Month: September 2019

Home / 2019 / September
26Sep 2019 by Erick ALverado

In the News: Forbes

In The News
SIWA therapeutics was mentioned in an article at Forbes! See what they had to say about senolytic therapies and the future of aging.
Read More

Recent Posts

  • BIO Digital 2020
  • In The News: SIWA Joins the fight against COVID-19
  • In the News: SIWA Featured on Chicago Business Journal
  • In the News: SIWA Therapeutics Joins the Ranks of SpaceX, Apple & Google with Our Inclusion in MIT Technology Reviews Top 10 Breakthrough Technologies of 2020.
  • In the News: Lewis and Misty Gruber Were Interviewed by Lifespan.io

Archives

  • May 2020
  • March 2020
  • February 2020
  • September 2019
  • March 2019
  • April 2018
  • January 2018
  • June 2017
  • May 2017
  • October 2016

Categories

  • Events
  • In The News
  • News
  • Press Releases

About Us

SIWA Therapeutics, Inc. is a pre-clinical stage company with a first-in-class humanized monoclonal antibody, SIWA 318H, that selectively targets both senescent cells and cancer cells.

Recent News

  • BIO Digital 2020
  • In The News: SIWA Joins the fight against COVID-19
  • In the News: SIWA Featured on Chicago Business Journal

JOIN OUR MAILING LIST

Navigation

  • Home
  • Leadership
  • Science
    • Senescence
    • Diseases
  • Data
    • SIWA 318
    • Data
    • Other Products
  • Media
    • News
    • Videos
  • Partners
  • Contact